

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number
WO 03/072713 A2

(51) International Patent Classification⁷: C12N
(21) International Application Number: PCT/US03/05147
(22) International Filing Date: 21 February 2003 (21.02.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/358,427 21 February 2002 (21.02.2002) US
(71) Applicant (for all designated States except US): BIO-
GEN, INC. [US/US]; 14 Cambridge Center, Cambridge,
MA 02142 (US).
(72) Inventors: and
(75) Inventors/Applicants (for US only): KALLED, Susan, L.
[US/US]; 100 Elsinore Street, Concord, MA 01742 (US).

REID, Hugh [AU/AU]; Department of Biochemistry and
Molecular Biology, Monash University, Clayton, Victoria
3800 (AU).


(74) Agent: GARRETT, Arthur, S.; Finnegan, Henderson,
Farabow, Garrett & Dunner, L.L.P., 1300 I Street, NW,
Washington, DC 20005-3315 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,

[Continued on next page]

(54) Title: USE OF BCMA AS AN IMMUNOREGULATORY AGENT



(57) Abstract: The disclosure relates to B-cell maturation antigen (BCMA), a receptor for APRIL and BAFF, and its use as an immunoregulatory agent in treatment of immunological disorders such as multiple sclerosis. The disclosure provides methods and compositions for treating neurodegenerative immunological disorders in mammals by administering soluble BCMA, an antibody against BCMA, or an antibody against a BCMA ligand, e.g., APRIL or BAFF.

WO 03/072713 A2